Share Name Share Symbol Market Type Share ISIN Share Description
Eco Animal Health Group Plc LSE:EAH London Ordinary Share GB0032036807 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 228.00 220.00 236.00 228.00 228.00 228.00 3,355 07:32:12
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 74.6 15.2 17.6 13.0 154

Eco Animal Health Share Discussion Threads

Showing 201 to 225 of 1100 messages
Chat Pages: Latest  20  19  18  17  16  15  14  13  12  11  10  9  Older
DateSubjectAuthorDiscuss
05/1/2011
13:16
Research is ongoing and results will be published in due course according to the last report on 8/12/10.
ltinvestor
05/1/2011
12:44
Someone has taken to these in the new year. Moves quickly when it gets going this one!
topvest
05/1/2011
11:41
I thought the US approval was expected before 2010, any ideas as to delay? thks!!
joeblogg2
05/1/2011
11:36
Vulgaris, given the cost of clinical trials, what evidence do you think would be needed from the raft of ongoing screens to justify initiating a trial? Is it a given that clinical trials would be required? I guess they would if their are no existing human data for Aivlosin although not sure if the primary focus would be safety or efficacy? Either way, it seems the share price is heading north in big leaps!
audigger
05/1/2011
11:25
Itinvestor. There are assertions that macrolide antibiotcs have some immun-modulatory /anti-inflammatory effect that may be relevant for influenza -- see e.g. http://www.ncbi.nlm.nih.gov/pubmed/16835706, along with the more specific assertions re. activity in cellular compartments made in the the patent and e.g. in for clarithromycin in http://www.ncbi.nlm.nih.gov/pubmed/20040578 However: 1) Macrolides have long beeen used in human respiratory infections. Most of these infection are viral not bacterial and the accepted view is that antibiotics are being mis-prescribed in these viral cases. If macrolides had a dramatic effect irrespective of whether the infection was viral or bacterial, this would have come to light in 50 years of use. Most obviously respiratory infection trials, (mis)including many patients with viral infections would have tended to favour macrolides over penicillin, where there is no assertion of anti-viral activity----- And they don't. Morevoer, were there serious antiival activity, companies like Pfizer (which had the patent on azithromycin) would have exploited it to the hilt esp when public health agencies began saying 'Don't prescribe for coughts & colds; they're viral'). 2) A patent, put together on some prima facie evidence, is not the same thing as a controlled trial and I can find now published controlled trial of Aivlosin in this context. I hold the stock long term, as part of an IHT mitigation strategy. I would be delighted if they got a boost from antiviral activity. But, I've also got 30+ years of expereince working on antibiotics and wouldn't bet the bank this flu assertion, interesting as it is!
vulgaris
04/1/2011
20:14
The patent makes intersting reading. Its not my field of expertise but the patent does suggest a mode of action for antiviral activity based on disruption of intralysosomal pH and prevention of replication rather than any enhancement of the immune system. What I find interesting is that it was the observation of antiviral efficacy in pigs being treated for bacterial infection that triggered this additional research. I've no idea how unique such an observation may be, but it suggests that tylvalosin may be more efficacious than some of its counterparts which may be more about bioavailability than intrinsic potency against the target. If this did prove a commercially viable option, then the upside would be huge. I'm invested soleley on the basis of the antibacterial application and the growth/profit that will come from US approval. Anything in addition to this would be a bonus!
audigger
04/1/2011
17:35
Vulgaris.Just following on from my previous post there is evidence that macrolide anti biotics have shown antiviral activity eg tilmocosin which was found to be too toxic.A US patent application was applied for in January 2010 regarding the antiviral properties of Aivlosin and is worth reading.The application number is 2010/0010080.
ltinvestor
04/1/2011
17:17
The Virology dept at Cambridge have been working on the antiviral properties of Aivlosin having received a £500k grant from the Medical Research Council.In its latest release Eco are continuing this research,I presume, as a result of findings.It appears to be active against the influenza virus and several other viruses and so is more specific than a general immune system stimulant.
ltinvestor
04/1/2011
16:43
AuDigger --- S Times tip predicated on likely FDA approval of Aivlosin; Itinvestor--- whilst there is research in the area I'd be sceptical of any macrolide antibacterial such as Aivlosin having antiviral proporties. They work by inhibiting the bacterial ribosome and viruses have no ribosomes, parasitising the (macrolide-uninhibited) human ones instead....... So, you'd have to postulate that the molecule has some other activity, perhaps by stimulating the immune system --- and there's lots of claims of that for lots of antibiotics over 50 years, but little you'd call hard proof of anything significant.
vulgaris
04/1/2011
16:36
>Audigger.Basically just says that US Aivlosin approval will be transformational for the company .
ltinvestor
04/1/2011
15:56
Very nice. Can someone please post the tip. I can't get on to Times online from my blackberry as subscription is required
audigger
04/1/2011
15:45
...... and nobody mentions the possible anti viral properties of Aivlosin !!
ltinvestor
04/1/2011
15:34
Sunday Times tip for 2011
vulgaris
08/12/2010
08:58
Overall very good results.Increased demand for products, cash in bank,profitable, new products to be introduced, tightly held shares and FDA approval perhaps within the next few months for its lead product.In addition the company, I presume as a result of results so far at Cambridge, are pursuing further research into the antiviral properties of Aivlosin.This macrolide antibiotic could become a blockbuster and I'll be very surprised if major pharmaceutical companies aren't already knocking on the door!!
ltinvestor
08/12/2010
07:31
Spooky sense of timing IT! Well you have to say that news is on the whole good. However, as I suspected FDA approval is delayed. I'm not entirely convinced that this is just becuase FDA haven't reviewed the data. They say.... "We understand that the Aivlosin� regulatory timeline has been extended by the Federal Drug Administration (FDA), owing to its excessive workload. The FDA is now unable to commit to the original review timeline for the final component of the development programme, which relates to laboratory testing. Although the approval timeline is not under ECO's control, the Company is making every effort to encourage the FDA to complete the approval of this final component as soon as possible" This is a little ambiguous. They are basically saying its FDA's fault they don't yet have approval. However, the qualifier "which relates to laboratory testing" suggests that FDA may not have concluded on the data they are reviewing as they have unresolved questions. They must have had correspondance with FDA so, for me, ECOs statement isn't as transparent as it should be. There is no mention of a timeframe which I also find unusual. Again, this may be just my lack of experience in dealing with FDA, so I'm not sure how they operate compared to other regulators. However, based on extensive experience of dealing with other regulators in the US and axcross the world, I believe ECO know more than they are communicating. That said, I remain fully optimistic they will get US approval and the revenue stream that comes with it and, in the meantime, the rest of the business is doing well.
audigger
07/12/2010
08:42
Have to say that its looking like FDA approval will be next year. If they operate anything like US EPA, they will be pretty much done with approving new products for 2010 by now. It does suggest ECO may be in discussions with FDA over some aspect of the approval. What I don't know, is whether FDA operate the same fee-based approval process that EPA now operate that requires them to grant the approval within a given timeframe after the applicant has submitted, assuming the data are complete and adequately address the safety and efficacy of the product. Will be interesting to see how the existing buisness has done and also if new EU approvals have had any impact on this yet.
audigger
06/12/2010
10:25
Half yearly report due soon according to last years reporting dates.Looking for update re progress obtaining FDA approval for Aivlosin and Cambridge research.
ltinvestor
09/11/2010
18:29
Very nice jump!
audigger
09/11/2010
11:45
Onwards and upwards !!FDA approval will be the icing on the cake.
ltinvestor
26/10/2010
11:28
All quiet on the EAH front. Hoping news of FDA approval is imminent.
audigger
08/10/2010
07:27
Lack of liquidity is always a problem with this type of share and you make a good point Pugugly that it can just as easily go south very quickly. However, it seems to be making a very sharp move up at around the time FDA approval is expected, so I'm speculating the two may be connected. Will be interesting to see if we get an RNS in relation to SP
audigger
08/10/2010
07:09
itinvestor:> As a long term holder little demand will also move it DOWN sharply. oNE HAS TO HAVE LONG TERM CONFIDENCE, as if bad news virtually impossible to sell.
pugugly
07/10/2010
11:40
Not sure but very tightly held so slightest demand will move it northwards fairly sharply.
ltinvestor
07/10/2010
11:27
Well something significant is afoot, must be FDA approval!
audigger
06/10/2010
18:17
Here we go, is this a jump ahead of significant news...?
audigger
Chat Pages: Latest  20  19  18  17  16  15  14  13  12  11  10  9  Older
Your Recent History
LSE
EAH
Eco Animal..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191115 08:36:27